SCHEMBL330670

SCHEMBL330670

COC(=O)c1cc(C(C)=O)ccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.65
CA1 P00915 4/20 0.65
CA2 P00918 4/20 0.65
CA7 P43166 4/20 0.65
CA9 Q16790 4/20 0.65
CA14 Q9ULX7 4/20 0.65
XDH P47989 2/20 0.56
LMNA P02545 3/20 0.53
TSHR P16473 2/20 0.53
PTGS2 P35354 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
HPGD P15428 3/20 0.51
HSD17B10 Q99714 3/20 0.51
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TP53 P04637 1/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31258831 1.00 CA12 (0.65) CA12CA1CA2CA7CA9
SCHEMBL5722171 0.91 TSHR (0.57) CA12CA1CA2CA7CA9
SCHEMBL403210 0.89 CA12 (0.71) CA12CA1CA2CA7CA9
SCHEMBL12040097 0.86 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL5082071 0.85 SMN1; SMN2 (0.65) CA12CA1CA2CA7CA9
SCHEMBL1647438 0.85 CA12 (0.65) CA12CA1CA2CA7CA9
SCHEMBL29826125 0.85 CA1 (0.67) CA12CA1CA2CA7CA9
SCHEMBL670644 0.85 CA1 (0.67) CA12CA1CA2CA7CA9
SCHEMBL4424415 0.84 CA1 (0.62) CA12CA1CA2CA7CA9
SCHEMBL7295677 0.82 PKM (0.57) MAPTHTTPKMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118240886-A Method for synthesizing ethyl salicylate compound by biological enzyme catalysis 济南大学 2024-06-25 CN claimed
CN-116687962-A Composition for preventing or treating diabetes and application thereof 青岛大学 2023-09-05 CN claimed
CN-111471523-B Spice composition with oxidation resistance 安徽华业香料合肥有限公司 2022-12-23 CN claimed
CN-111471523-A Spice composition with oxidation resistance 安徽华业香料合肥有限公司 2020-07-31 CN claimed
US-10191398-B2 Electrophotographic photoconductor, image forming apparatus, and process cartridge RICOH COMPANY, LTD. (JP) 2019-01-29 US claimed
CN-105685021-A Insecticide mother liquor and application thereof 中山榄菊日化实业有限公司 2016-06-22 CN claimed
EP-1053997-B1 Process for the preparation of linear acrylonitril dimers SALTIGO GMBH (DE) 2007-02-28 EP claimed
CN-1290818-C Method for asymmetrical hydrogen transfer of alpha-imino keton for synthesizing chirality salbutamol UNIV EAST CHINA NORMAL (CN) 2006-12-20 CN claimed
CN-1733701-A Method for asymmetrical hydrogen transfer of alpha-imino keton for synthesizing chirality salbutamol UNIV EAST CHINA NORMAL (CN) 2006-02-15 CN claimed
EP-0763010-B1 ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL SEPRACOR INC (US) 2000-08-30 EP claimed
EP-0763010-A4 ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL SEPRACOR INC (US) 1997-07-16 EP claimed
EP-0763010-A1 ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL SEPRACOR, INC. (US) 1997-03-19 EP claimed
WO-1995032178-A1 ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL SEPRACOR, INC. (US) 1995-11-30 WO claimed
US-5399765-A Salt formation SEPRACOR, INC. (US) 1995-03-21 US claimed
CN-116687962-B Composition for preventing or treating diabetes and application thereof QINGDAO UNIVERSITY (CN) 2026-05-26 CN disclosed
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels THE CLEVELAND CLINIC FOUNDATION (US) 2026-03-17 US disclosed
CN-119707716-A Preparation method of salbutamol 浙江雅辰药物科技股份有限公司 2025-03-28 CN disclosed
US-4255575-A HYPOTENSIVE, ANTISPASMODIC, ADRENERGIC BLOCKING AGENTS RICHARDSON-MERRELL INC. (US) 1981-03-10 US disclosed
EP-0018830-A2 Spirobenzofuranones, their production and pharmaceutical compositions containing them Takeda Chemical Industries, Ltd. (JP) 1980-11-12 EP disclosed
US-4221808-A Novel antihypertensive agent RICHARDSON-MERRELL INC. (US) 1980-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels BHMT, BHMT2, EHMT2 CA12 1832/4885CA1 2402/4885CA2 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.